{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-022762","form_type":"8-K","ticker":"FEMY","cik":"0001339005","company_name":"FEMASYS INC","filed_at":"2025-06-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.018066+00:00","generated_at":"2026-05-19T04:25:41.998576+00:00","sec_items":["8.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Femasys appoints Kelley Nicholas as CCO; grants 100,000-share inducement option","bullets":["Appointed Kelley Nicholas as Chief Commercial Officer effective June 17, 2025; she will lead U.S. commercialization and global partnerships.","Nicholas brings over 25 years experience from NeuroPace, Hologic, Medtronic, Baxter, Intuitive Surgical.","As inducement, Femasys granted option to purchase 100,000 shares vesting over 4 years (25% after 1 year, then 25% annually).","Focus on expanding U.S. infertility market for FemaSeed and building international partnerships across full portfolio."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-022762","json":"https://secwatch.observer/filing/0001140361-25-022762.json","markdown":"https://secwatch.observer/filing/0001140361-25-022762.md","text":"https://secwatch.observer/filing/0001140361-25-022762.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1339005/000114036125022762/0001140361-25-022762-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1339005/000114036125022762/ef20050687_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T04:25:41.998576+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}